CalciMedica, Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica, Inc. (NASDAQ:CALC) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 24,800 shares, an increase of 13.8% from the July 15th total of 21,800 shares. Currently, 0.6% of the company’s shares are sold short. Based on an average daily volume of 40,100 shares, the short-interest ratio is presently 0.6 days.

Insiders Place Their Bets

In other news, Director Robert N. Wilson acquired 8,443 shares of the firm’s stock in a transaction on Thursday, June 27th. The stock was acquired at an average price of $3.23 per share, with a total value of $27,270.89. Following the completion of the purchase, the director now directly owns 258,918 shares in the company, valued at $836,305.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 53.30% of the stock is owned by insiders.

Institutional Trading of CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Meritage Portfolio Management increased its holdings in CalciMedica, Inc. (NASDAQ:CALC) by 360.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,000 shares of the company’s stock after buying an additional 36,000 shares during the period. Meritage Portfolio Management owned about 0.81% of CalciMedica worth $132,000 as of its most recent filing with the Securities & Exchange Commission.

Analyst Upgrades and Downgrades

CALC has been the subject of several analyst reports. Singular Research raised shares of CalciMedica to a “moderate buy” rating in a research note on Friday, June 28th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of CalciMedica in a research note on Tuesday, August 13th. Finally, Oppenheimer raised their price objective on shares of CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 10th.

CalciMedica Trading Up 2.1 %

Shares of CalciMedica stock traded up $0.09 on Friday, hitting $4.19. 10,836 shares of the company traded hands, compared to its average volume of 28,587. The stock’s 50 day moving average price is $4.54 and its 200-day moving average price is $4.73. CalciMedica has a 52 week low of $1.75 and a 52 week high of $8.38. The company has a market cap of $45.01 million, a PE ratio of -1.95 and a beta of 1.28.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.